Sean A. Mccarthy Sells 20,223 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMXGet Free Report) CEO Sean A. Mccarthy sold 20,223 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.09, for a total value of $42,266.07. Following the sale, the chief executive officer now owns 524,481 shares in the company, valued at approximately $1,096,165.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

CytomX Therapeutics Stock Down 1.3 %

CTMX stock traded down $0.03 during trading on Thursday, hitting $2.24. The company had a trading volume of 667,998 shares, compared to its average volume of 922,362. The firm has a market cap of $151.69 million, a PE ratio of -111.94 and a beta of 1.02. CytomX Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $2.86. The firm has a 50-day moving average price of $1.84 and a 200-day moving average price of $1.52.

Hedge Funds Weigh In On CytomX Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in shares of CytomX Therapeutics by 0.6% during the 1st quarter. BlackRock Inc. now owns 4,992,094 shares of the biotechnology company’s stock worth $13,328,000 after acquiring an additional 29,732 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in CytomX Therapeutics by 55.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 809,140 shares of the biotechnology company’s stock valued at $2,161,000 after buying an additional 287,113 shares during the last quarter. Vanguard Group Inc. grew its holdings in CytomX Therapeutics by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 5,222,886 shares of the biotechnology company’s stock valued at $13,945,000 after buying an additional 114,895 shares during the last quarter. Mackenzie Financial Corp acquired a new stake in CytomX Therapeutics during the 1st quarter valued at $35,000. Finally, XTX Topco Ltd grew its holdings in CytomX Therapeutics by 1,064.2% during the 1st quarter. XTX Topco Ltd now owns 118,339 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 108,174 shares during the last quarter. Institutional investors and hedge funds own 51.11% of the company’s stock.

About CytomX Therapeutics

(Get Free Report)

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.

Further Reading

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.